Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- Cancer Advocate Warns of Lack of Patient Involvement in CEA Debates
August 30, 2017
- Impact of Drug Price Revisions on Company Management Unclear: JMA Think Tank
August 22, 2017
- JPWA Member Firms Suffer Record 3.5% Sales Fall on Drop-Off in Demand for Hepatitis C Meds
August 16, 2017
- Science Council of Japan Calls for Public-Private Partnerships to Spur Development of Psychiatric Disease Treatments
August 9, 2017
- New Chuikyo Doctor Reps Question Drug Pricing Premiums, CEA Plan
July 19, 2017
- EFPIA Japan to Provide 1 Million Yen to Support Patients’ Organizations
July 5, 2017
- Generic Use Rate at 65.5% in FY2016: JGA
June 30, 2017
- JMA Announces Endorsement for Chuikyo Rep Replacements
June 26, 2017
- FPMAJ Weighs Refined Version of “Similar Treatment Comparison” Pricing Method
June 20, 2017
- FPMAJ “Not Opposed” to Company Requirements for Receiving Price Maintenance Premium: Kamoya
June 20, 2017
- Reflecting Results of CEA in NHI Prices at Time of Listing Will Be Difficult: FPMAJ Report
June 20, 2017
- FPMAJ Calls for “Cautious” Discussions on Reduction of Price Band for Generic Drugs
June 19, 2017
- FPMAJ Calls for Maintaining Prices for On-Patent Drugs, Lower Price Reduction Rates in Off-Year Revisions
June 19, 2017
- JGA Appreciates Tweaked Honebuto Text on Generics, 80% Goal Achievable on Production Basis
June 13, 2017
- JMA’s Nakagawa Questions Price Difference for LLPs and AGs, Negative about PhRMA Pitch for AWP Alternatives
June 9, 2017
- Membership of Japan Biosimilar Association to Reach 20 Companies in Near Future
June 7, 2017
- Public, Private Donors Put Up US$200-Plus Million for GHIT’s 2nd-Phase Work
June 5, 2017
- Japan Drug Market Could Shrink at CAGR of -2.5% If Price Maintenance Premium Scrapped: EFPIA
June 1, 2017
- JGA Ups Its Lobbying Efforts to Prevent Further Reduction in Price Bands for Generics
June 1, 2017
- Maker FTC Sanctions Member Company for Violating Fair Competition Code
May 30, 2017
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…